Solid Tumor Therapeutics Market Competitive Research And Precise Outlook 2020 To 2026

The Solid Tumor Therapeutics Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2026. The Solid Tumor Therapeutics market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types and end industries. This Solid Tumor Therapeutics Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

Top Companies in the Global Solid Tumor Therapeutics Market
Hoffmann-La Roche, Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS), AstraZeneca PLC (NYSE:AZN), Biogen Idec, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Kyowa Hakko Kirin, Abbott Laboratories, Baxter International, among others.

The global Solid Tumor Therapeutics Market to grow with a CAGR of 16.1% over the forecast period of 2021-2026.

Market Overview:
The major factors that are responsible for the growth of this market include new product approvals in ovarian, pancreatic, and prostate cancers, and increasing government initiatives for cancer awareness. In addition, the other crucial driving factor is the increasing incidence of cancer. For instance, cancer has a significant impact on societies across the world.

Get Free Sample PDF Copy of Latest Research on Solid Tumor Therapeutics Market 2020 Before the purchase
https://www.marketinsightsreports.com/reports/04061949500/global-solid-tumor-therapeutics-market-size-status-and-forecast-2020-2026/inquiry?Mode=46&Source=Openpr

Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners could prevent this trend and prevent as many as one-third of all cancers, worldwide. The American Cancer Society, the leading body in cancer stats and figures, reports 1,685,210 estimated new cancer cases and 595,690 deaths, due to cancer in 2016, in the United States. Hence, the increasing number of patients is expected to drive the market during the forecast period.

Key Market Trends
Breast Cancer is Expected to Hold the Major Revenue Share in the Type of Cancer Segment
Breast cancer is one of the major cancer types for which new immune-based cancer treatments are currently in development. More than 80% of all cancers are caused by solid tumors that grow as a mass of cells in a particular organ, tissue or gland. According to the American Cancer Society, as of 2018, it is estimated that approximately 268,670 new breast cancer cases are expected in the United States. And even several major companies are investing in the development of new treatments for cancers. For example, Ibrance (palbociclib) by Pfizer is for the treatment of ER-positive, HER2-negative breast cancer and has been approved in February 2015. A trial of the use of two drugs in combination found that tumors were completely cleared in 11% of patients with HER2-positive breast cancer and were reduced to minimal size in a further 17%. Nearly 90% saw a reduction in the number of cancer cells. Hence, with the entry of new drugs the segment is expected to continue its lead as the number of cases is also helping in the growth.

North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the market for solid tumor therapeutics, and it is expected to continue its stronghold for a few more years. In North America, the United States holds the largest market share. This can be majorly attributed to increasing incidence rates of cancer and increasing awareness among people, and the presence of developed healthcare infrastructure are propelling the growth of the market in the forecast period.

Key Developments in the Market
August 2017: Bristol-Myers Squibb acquired IFM Therapeutics to strengthen its oncology segment.
October 2017: Abbott completed the acquisition of Alere.

Trending News
Johnson & Johnson (NYSE:JNJ)
-ERLEADA (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
RARITAN, NJ, May 13, 2020 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th.

(Source- jnj.com )

AstraZeneca PLC (NYSE:AZN)
-Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer
20 May 2020 07:00: AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
The approval by the US Food and Drug Administration (FDA) was based on results from the Phase III PROfound trial, which were published in The New England Journal of Medicine.
Prostate cancer is the second-most common cancer in men and despite an increase in the number of available therapies for men with mCRPC, five-year survival remains low. HRR gene mutations occur in approximately 20-30% of patients with mCRPC.

The Solid Tumor Therapeutics market can be divided based on product types and its sub-type, major applications and Third Party usage area, and important regions.

This report segments the global Solid Tumor Therapeutics Market on the basis of Types are
Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy

On The basis Of Application, the Global Solid Tumor Therapeutics Market is Segmented into
Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Others

(Exclusive Offer: Flat 30% discount on this report)
Inquire for Discount
https://www.marketinsightsreports.com/reports/04061949500/global-solid-tumor-therapeutics-market-size-status-and-forecast-2020-2026/discount?Mode=46&Source=Openpr

Regions Are covered By Solid Tumor Therapeutics Market Report 2020 To 2026.

North America, Europe, China, Japan, Southeast Asia, India.
North America (USA, Canada and Mexico).
Europe (Germany, France, UK, Russia and Italy).
Asia-Pacific (China, Japan, Korea, India and Southeast Asia).

Significant Features that are under Offering and Key Highlights of the Reports:

-Detailed overview of Solid Tumor Therapeutics Market
-Changing Solid Tumor Therapeutics market dynamics of the industry
-In-depth market segmentation by Type, Application etc.
-Historical, current and projected Solid Tumor Therapeutics market size in terms of volume and value
Recent industry trends and developments
-Competitive landscape of Solid Tumor Therapeutics Market
-Strategies of key players and product offerings
-Potential and niche segments/regions exhibiting promising growth.

Frequently Asked Questions about Solid Tumor Therapeutics market:

- What are the recent developments and government policies?
- Why might we forecast a downturn in a particular economy next year?
- Why do we say a currency is set to appreciate?
- What countries and sectors offer the highest potential?
- Where are the greatest dangers?

The report has 150 tables and figures browse the report description and TOC
https://www.marketinsightsreports.com/reports/04061949500/global-solid-tumor-therapeutics-market-size-status-and-forecast-2020-2026?Mode=46&Source=Openpr

We Also Offer Customization on report based on specific client Requirement
Free country Level analysis for any 5 countries of your choice.
Free Competitive analysis of any 5 key market players.
Free 40 analyst hours to cover any other data point.

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Market Insights Reports
4893, Pepper drive, Harrisburg ,NC 28075,United States

Contact US :

Irfan Tamboli (Head of Sales)
Market Insights Reports
Phone: + 1704 266 3234 | Mob: +91-750-707-8687
sales@marketinsightsreports.com
irfan@marketinsightsreports.com

ABOUT US

Market Insights Reports is an online market research reports library of 500,000 in-depth studies of over 5000 micro markets. Market Insights Reports offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

This release was published on openPR.